(RTTNews) - As August approaches, it's time for our regular review of the critical FDA decisions on the horizon.
So far this year, 22 novel drugs have been approved by the FDA compared to 29 during the same period last year. ("Novel" drugs are new drugs never before approved or marketed in the U.S.: Source: FDA).
Separately, August is observed as spinal muscular atrophy (SMA) awareness month. SMA is a rare genetic neurodegenerative disorder characterized by the loss of motor neurons, atrophy of the voluntary muscles of the limbs and trunk and progressive muscle weakness.
Typically, fatal and commonly diagnosed in young children, SMA has no complete cure. However, approved therapies can manage the symptoms of this neuromuscular disease. Notable treatments include Biogen's Spinraza, Novartis' Zolgensma, and Roche's Evrysdi.
FDA decisions can make or break biotech stocks. Stay ahead of the market by accessing detailed insights and analysis. Don't miss out on these potential game-changers.
Click here now to uncover the biotech stocks poised for action this August!
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
